An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment
Latest Information Update: 19 Jul 2024
At a glance
- Drugs Pasireotide (Primary) ; Pasireotide (Primary) ; Cabergoline
- Indications Acromegaly; Dumping syndrome; Pituitary ACTH hypersecretion
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals; Recordati
- 31 May 2024 Status changed from active, no longer recruiting to completed.
- 19 Jan 2024 This trial has been completed in France (Global end date: 25 July 2023).
- 23 Sep 2023 This trial has been completed in Spain, according to European Clinical Trials Database record.